Alternating cisplatinum and VAC ineffective in end stage squamous cell carcinoma of the head and neck
- 1 February 1990
- journal article
- research article
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- Vol. 104 (8) , 631-633
- https://doi.org/10.1017/s0022215100113441
Abstract
Sixteen patients with end stage squamous cell carcinoma of the head and neck were admitted to a phase II study of alternating courses of cisplatinum (100mg/m2) and VAC (vincristine 1.4mg/m2, adriamycin 50 mg/m2, cyclophosphamide 750 mg/m2) given at three weekly intervals. Only two patients achieved a response (12 per cent). The median survival time was 62 days which is much the same as that of a similar group of patients who received no chemotherapy in a previous trial (70 days).This publication has 14 references indexed in Scilit:
- A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neckBritish Journal of Cancer, 1990
- Multidrug Resistance in CancerScientific American, 1989
- A phase II trial of cyclophosphamide and adriamycin in refractory squamous cell carcinoma of the head and neckAmerican Journal of Clinical Oncology, 1985
- A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neckCancer, 1983
- Adjuvant chemotherapy with Cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neckCancer, 1983
- Reporting results of cancer treatmentCancer, 1981